200 related articles for article (PubMed ID: 25754026)
21. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
[TBL] [Abstract][Full Text] [Related]
22. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Wang Y; Zhang D; Zheng W; Luo J; Bai Y; Lu Z
Cancer; 2008 Mar; 112(6):1325-36. PubMed ID: 18286531
[TBL] [Abstract][Full Text] [Related]
23. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
[TBL] [Abstract][Full Text] [Related]
24. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
[TBL] [Abstract][Full Text] [Related]
25. Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients.
Andjelkovic T; Bankovic J; Milosevic Z; Stojsic J; Milinkovic V; Pesic M; Ruzdijic S; Tanic N
Cancer Biomark; 2011-2012; 10(6):277-86. PubMed ID: 22820083
[TBL] [Abstract][Full Text] [Related]
26. Gene methylation as a powerful biomarker for detection and screening of non-small cell lung cancer in blood.
Wang BH; Li YY; Han JZ; Zhou LY; Lv YQ; Zhang HL; Zhao L
Oncotarget; 2017 May; 8(19):31692-31704. PubMed ID: 28404957
[TBL] [Abstract][Full Text] [Related]
27. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
28. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.
Belinsky SA; Palmisano WA; Gilliland FD; Crooks LA; Divine KK; Winters SA; Grimes MJ; Harms HJ; Tellez CS; Smith TM; Moots PP; Lechner JF; Stidley CA; Crowell RE
Cancer Res; 2002 Apr; 62(8):2370-7. PubMed ID: 11956099
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.
Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G
Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers.
Hanabata T; Tsukuda K; Toyooka S; Yano M; Aoe M; Nagahiro I; Sano Y; Date H; Shimizu N
Oncol Rep; 2004 Jul; 12(1):177-80. PubMed ID: 15201980
[TBL] [Abstract][Full Text] [Related]
31. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
32. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication.
Shimamoto T; Ohyashiki JH; Hirano T; Kato H; Ohyashiki K
Oncol Rep; 2004 Aug; 12(2):389-95. PubMed ID: 15254707
[TBL] [Abstract][Full Text] [Related]
33. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
34. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
35. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
36. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion.
Katayama H; Hiraki A; Aoe K; Fujiwara K; Matsuo K; Maeda T; Murakami T; Toyooka S; Sugi K; Ueoka H; Tanimoto M
Int J Cancer; 2007 May; 120(10):2191-5. PubMed ID: 17285579
[TBL] [Abstract][Full Text] [Related]
37. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387
[TBL] [Abstract][Full Text] [Related]
38. Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis.
Huang T; Li J; Zhang C; Hong Q; Jiang D; Ye M; Duan S
PLoS One; 2016; 11(2):e0149088. PubMed ID: 26862903
[TBL] [Abstract][Full Text] [Related]
39. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
40. Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood.
Tan S; Sun C; Wei X; Li Y; Wu Y; Yan Z; Feng F; Wang J; Wu Y
Exp Lung Res; 2013; 39(4-5):182-90. PubMed ID: 23614702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
